MCID: HPT016
MIFTS: 68

Hepatitis B

Categories: Rare diseases, Infectious diseases, Liver diseases, Gastrointestinal diseases, Immune diseases, Genetic diseases

Aliases & Classifications for Hepatitis B

MalaCards integrated aliases for Hepatitis B:

Name: Hepatitis B 37 12 72 51 40 41 14 69
Hepatitis B, Chronic 41 69
Hepatitis B Infection 12
Chronic Hepatitis B 12
Hepatitis B Chronic 51
Serum Hepatitis 12
Hbv 44

Classifications:



External Ids:

Disease Ontology 12 DOID:2043
NCIt 46 C3097

Summaries for Hepatitis B

MedlinePlus : 40 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. One type, hepatitis B, is caused by the hepatitis B virus (HBV). Hepatitis B spreads by contact with an infected person's blood, semen, or other body fluid. An infected woman can give hepatitis B to her baby at birth. If you get HBV, you may feel as if you have the flu. You may also have jaundice, a yellowing of skin and eyes, dark-colored urine, and pale bowel movements. Some people have no symptoms at all. A blood test can tell if you have it. HBV usually gets better on its own after a few months. If it does not get better, it is called chronic HBV, which lasts a lifetime. Chronic HBV can lead to cirrhosis (scarring of the liver), liver failure, or liver cancer. There is a vaccine for HBV. It requires three shots. All babies should get the vaccine, but older children and adults can get it too. If you travel to countries where Hepatitis B is common, you should get the vaccine. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis B, also known as hepatitis b, chronic, is related to hepatitis d and rheumatic disease, and has symptoms including fever, fatigue and loss of appetite. An important gene associated with Hepatitis B is LAMTOR5 (Late Endosomal/Lysosomal Adaptor, MAPK And MTOR Activator 5), and among its related pathways/superpathways are RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways and Tuberculosis. The drugs Emtricitabine and Adefovir Dipivoxil have been mentioned in the context of this disorder. Affiliated tissues include liver, liver and t cells, and related phenotype is mortality/aging.

Disease Ontology : 12 A viral infectious disease that results_in inflammation located in liver, has material basis in Hepatitis B virus, which is transmitted_by sexual contact, transmitted_by blood transfusions, and transmitted_by fomites like needles or syringes. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 72 Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) that affects the liver. It... more...

Related Diseases for Hepatitis B

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis B via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 488)
# Related Disease Score Top Affiliating Genes
1 hepatitis d 33.4 F2 GPT IFNA2
2 rheumatic disease 30.7 IFNA1 IFNG TNF
3 cryoglobulinemia, familial mixed 30.6 IFNA1 IFNA2
4 hepatitis 30.6 AFP F2 GGT1 GPT IFNA1 IFNA2
5 liver disease 30.3 AFP ALB F2 GGT1 GPT IFNA1
6 acute liver failure 30.2 ALB F2 GPT SLC17A5
7 mouth disease 30.2 IFNA1 IFNG TNF
8 portal hypertension 30.1 ALB F2 GPT TNF
9 non-a-e hepatitis 30.1 ALB F2
10 typhoid fever 30.1 ALB IFNG TNF
11 schistosomiasis 30.1 ALB F2 IFNG TNF
12 hepatitis e 30.0 ALB F2 GPT IFNG TNF
13 hypersplenism 30.0 ALB F2 IFNG
14 hepatitis c 30.0 AFP GGT1 GPT IFNA1 IFNA2 IFNG
15 acquired immunodeficiency syndrome 29.9 ALB IFNA1 IFNA2 IFNG TNF
16 biliary atresia 29.9 ALB GPT SLC10A1
17 hepatitis a 29.9 AFP ALB F2 GPT IFNA2 TNF
18 peritonitis 29.8 ALB F2 IFNG TNF
19 meningitis 29.8 ALB IFNG MBL2 TNF
20 nonalcoholic steatohepatitis 29.7 F2 GPT SLC17A5 TNF
21 cholecystitis 29.6 ALB F2 GPT
22 alcoholic liver cirrhosis 29.6 ALB F2 SLC17A5 TNF
23 systemic lupus erythematosus 29.6 ALB F2 IFNA1 IFNG MBL2 TNF
24 alcoholic hepatitis 29.6 ALB F2 GPT SLC17A5 TNF
25 endocarditis 29.6 ALB F2 TNF
26 esophageal varix 29.6 AFP ALB F2
27 fascioliasis 29.6 ALB GPT IFNG SLC17A5
28 eclampsia 29.5 ALB F2 TNF
29 fatty liver disease 29.5 GGT1 GPT SLC17A5 TNF
30 autoimmune hepatitis 29.5 F2 GGT1 GPT
31 hepatic encephalopathy 29.4 ALB F2 GPT SLC17A5 TNF
32 hellp syndrome 29.2 F2 GPT SLC17A5
33 liver cirrhosis 29.1 AFP ALB F2 GGT1 GPT IFNA1
34 viral hepatitis 29.0 AFP ALB F2 GGT1 GPT IFNA1
35 alcohol abuse 29.0 GGT1 GPT SLC17A5
36 hemorrhagic fever 29.0 ALB F2 GPT IFNG SLC17A5 TNF
37 cholangitis 28.9 ALB F2 GGT1 GPT TNF
38 primary biliary cirrhosis 28.9 ALB F2 GGT1 GPT SLC17A5
39 cholestasis 28.9 F2 GGT1 GPT SLC10A1
40 bilirubin metabolic disorder 28.8 ALB F2 GGT1 GPT
41 intrahepatic cholestasis 28.1 ALB GGT1 SLC17A5
42 hepatitis b vaccine, response to 12.2
43 hepatitis b reinfection following liver transplantation 12.0
44 hepatocellular carcinoma 11.6
45 gianotti crosti syndrome 11.3
46 membranous nephropathy 11.2
47 acrodermatitis 11.2
48 hepatoblastoma 11.2
49 childhood hepatocellular carcinoma 11.2
50 lymphomatoid granulomatosis 10.7 IFNA1 IFNA2

Graphical network of the top 20 diseases related to Hepatitis B:



Diseases related to Hepatitis B

Symptoms & Phenotypes for Hepatitis B

Symptoms:

12
  • fever
  • fatigue
  • loss of appetite
  • nausea
  • vomiting
  • abdominal pain
  • clay-colored bowel movements
  • joint pain
  • jaundice

UMLS symptoms related to Hepatitis B:


gastrointestinal gas, pruritus, nausea and vomiting, icterus, heartburn, fever, dyspepsia, diarrhea, constipation, abdominal pain

MGI Mouse Phenotypes related to Hepatitis B:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.44 AFP AIP ALB DDB1 DDX3X F2

Drugs & Therapeutics for Hepatitis B

Drugs for Hepatitis B (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 462)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2 143491-57-0 60877
2
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142340-99-6 60871
3
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
4
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 21645-51-2
5
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
6
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 198153-51-4 5360545
7
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
8
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3424-98-4 159269
9
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1 215647-85-1, 99210-65-8
10
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
11
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
12
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1 36791-04-5 37542
13
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
14
Ethiodized oil Approved, Investigational Phase 4,Phase 2,Phase 3 8008-53-5
15
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
16
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
17
Mycophenolic acid Approved Phase 4 24280-93-1 446541
18
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
19
Thymalfasin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 62304-98-7
20 Simethicone Approved Phase 4,Phase 3
21
rituximab Approved Phase 4,Phase 2,Phase 3 174722-31-7 10201696
22
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
23
Zidovudine Approved Phase 4,Phase 2 30516-87-1 35370
24
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 155213-67-5 392622
25
Lenograstim Approved, Investigational Phase 4,Phase 1,Phase 2 135968-09-1
26
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2 376348-65-1 3002977
27
Ethanol Approved Phase 4,Phase 1 64-17-5 702
28
Ledipasvir Approved Phase 4,Phase 2,Phase 3 1256388-51-8 67505836
29
Sofosbuvir Approved Phase 4,Phase 2,Phase 3 1190307-88-0 45375808
30
chloroquine Approved, Investigational, Vet_approved Phase 4,Phase 1 54-05-7 2719
31
Adalimumab Approved Phase 4 331731-18-1 16219006
32
Etanercept Approved, Investigational Phase 4 185243-69-0
33
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
34
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
35
Acetaminophen Approved Phase 4,Phase 3,Phase 2 103-90-2 1983
36
Ibuprofen Approved Phase 4 15687-27-1 3672
37
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
38
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
39
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
40
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787
41
Alprostadil Approved, Investigational Phase 4,Phase 1,Phase 2 745-65-3 149351
42
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3 93-14-1 3516
43
Methadone Approved Phase 4,Phase 3 76-99-3 4095
44
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
45
Etravirine Approved Phase 4 269055-15-4 193962
46
Abacavir Approved, Investigational Phase 4,Phase 2 136470-78-5 441300 65140
47
Metformin Approved Phase 4 657-24-9 4091 14219
48 Dolutegravir Approved Phase 4,Phase 2 1051375-16-6 54726191
49
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
50 Tocopherol Approved, Investigational, Nutraceutical Phase 4

Interventional clinical trials:

(show top 50) (show all 1495)

# Name Status NCT ID Phase Drugs
1 A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults Unknown status NCT02203357 Phase 4
2 Adolescents' Response to Hepatitis B Vaccine Booster Dose Unknown status NCT01341275 Phase 4
3 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
4 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
5 Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
6 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
7 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
8 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
9 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
10 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
11 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
12 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
13 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
14 Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
15 The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
16 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
17 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
18 Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy Unknown status NCT01928511 Phase 4 peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly;Nucleos(t)ide analogue therapy
19 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
20 Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
21 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
22 Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
23 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4 telbivudine
24 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
25 Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir Unknown status NCT02241590 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
26 Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
27 Prednisolone Priming Study in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4 Prednisolone;Placebo priming
28 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B Unknown status NCT00921180 Phase 4 Entecavir and peginterferon alfa-2a;Placebo and peginterferon
29 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B Unknown status NCT00917761 Phase 4 Entecavir and peginterferon (Pegasys) (52 weeks);Peginterferon (Pegasys) (96 weeks);Peginterferon (Pegasys) (48 weeks)
30 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
31 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
32 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
33 Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude Unknown status NCT02523547 Phase 4 Cavir;Baraclude
34 A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone Unknown status NCT00354653 Phase 4 LAMIVUDINE
35 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
36 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
37 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4 Telbivudine
38 Efficacy and Safety Study of Telbivudine to Prevent Perinatal Transmission Unknown status NCT00939068 Phase 4 Telbivudine
39 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
40 A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Unknown status NCT01965418 Phase 4 Fufang Biejia Ruangan Tablet;Placebo
41 HBsAg Related Response Guided Therapy Unknown status NCT01456312 Phase 4 Peginterferon alfa-2a;Entecavir
42 Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01829685 Phase 4 Entecavir, Adefovir
43 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
44 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection Unknown status NCT00810524 Phase 4 lamivudine;Telbivudine;Enticavir;Adefovir Dipivoxil Tablets
45 EFFORT Extension Study Unknown status NCT01529255 Phase 4 telbivudine (ROADMAP);Telbivudine (Standard of Care)
46 A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4 Entacavir;Tenofovir
47 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4 Entecavir
48 An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients Unknown status NCT02560649 Phase 4 Peginterferon alfa-2a plus Entecavir;Peginterferon alfa-2a plus Lamivudine;Peginterferon alfa-2a plus Adefovir;Peginterferon alfa-2a plus Tenofovir;Entecavir;Lamivudine;Adefovir;Tenofovir disoproxil
49 3E Extension Study Unknown status NCT01834508 Phase 4 oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
50 Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV Unknown status NCT02241616 Phase 4 Entecavir+Fuzheng Huayu+TCM Granule

Search NIH Clinical Center for Hepatitis B

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis B cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis B:
Bone marrow-derived mesenchymal stem cells for treatment of liver failure
Embryonic/Adult Cultured Cells Related to Hepatitis B:
Bone marrow-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: hepatitis b

Genetic Tests for Hepatitis B

Anatomical Context for Hepatitis B

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis B:

18
Liver

MalaCards organs/tissues related to Hepatitis B:

38
Liver, T Cells, Testes, Kidney, Bone, Skin, Bone Marrow

Publications for Hepatitis B

Articles related to Hepatitis B:

(show top 50) (show all 4659)
# Title Authors Year
1
Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. ( 29447061 )
2018
2
Implementation of hepatitis B birth dose vaccination a89 worldwide, 2016. ( 29450989 )
2018
3
Effect of tenofovir on renal function in patients with chronic hepatitis B. ( 29443737 )
2018
4
Correction: An ImmunoSignature test distinguishes Trypanosoma cruzi, hepatitis B, hepatitis C and West Nile virus seropositivity among asymptomatic blood donors. ( 29389963 )
2018
5
Hepatitis B virus genotypes A1, A2 and E in Cape Verde: Unequal distribution through the islands and association with human flows. ( 29447232 )
2018
6
Hepatitis A and hepatitis B vaccination coverage among adults with chronic liver disease. ( 29395521 )
2018
7
Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. ( 29336924 )
2018
8
Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B. ( 29447614 )
2018
9
The disseminated intravascular coagulation score is a novel predictor for portal vein thrombosis in cirrhotic patients with hepatitis B. ( 29178991 )
2018
10
Quantitative assessment of HLA-DQ gene polymorphisms with the development of hepatitis B virus infection, clearance, liver cirrhosis, and hepatocellular carcinoma. ( 29416599 )
2018
11
Prevalence of Hepatitis B virus and Hepatitis D virus coinfection in Western Burkina Faso and molecular characterization of the detected virus strains. ( 29432880 )
2018
12
Identification of key candidate genes and pathways in hepatitis B virus-associated acute liver failure by bioinformatical analysis. ( 29384847 )
2018
13
Assessment of Humoral Immunity to Hepatitis B, Measles, Rubella, and Mumps in Children After Chemotherapy. ( 29309372 )
2018
14
3D microfluidic liver cultures asA a physiological preclinical tool for hepatitis B virus infection. ( 29445209 )
2018
15
Molecular evolution and phylodynamics of hepatitis B virus infection circulating in Iran. ( 29442226 )
2018
16
What Are the Main Differences in the Treatment of Chronic Hepatitis B between Korean Children and Adults? ( 29441758 )
2018
17
Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs. ( 29451182 )
2018
18
Hepatitis B virus Reactivation During Steroid Treatment of IgG4-Related Disease. ( 29311390 )
2018
19
Solid-state [<sup>13</sup>C-<sup>15</sup>N] NMR resonance assignment of hepatitis B virus core protein. ( 29450824 )
2018
20
PREVALENCE OF OCCULT HEPATITIS B IN A POPULATION FROM THE BRAZILIAN AMAZON REGION. ( 29446468 )
2018
21
Evaluation of a convenient vaccination schedule against hepatitis B in HIV-patients with undetectable HIV viral load. ( 29449101 )
2018
22
Fluorescent protein tagged hepatitis B virus capsid protein with long glycine-serine linker that supports nucleocapsid formation. ( 29447911 )
2018
23
A cross-sectional study of the relationship between infant Thimerosal-containing hepatitis B vaccine exposure and attention-deficit/hyperactivity disorder. ( 29413097 )
2018
24
Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characters: a pilot open-lable randomized study. ( 29452204 )
2018
25
Utilization of hepatitis B core antibody positive grafts in living donor liver transplantation. ( 29450703 )
2018
26
Early Combination Therapy with Corticosteroid and Nucleoside Analogue Induces Rapid Resolution of Inflammation in Acute Liver Failure Due to Transient Hepatitis B Virus Infection. ( 29321429 )
2018
27
Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B. ( 29444493 )
2018
28
MiR-27a as a predictor for the activation of hepatic stellate cells and hepatitis B virus-induced liver cirrhosis. ( 29416678 )
2018
29
Immunoreaction-Mediated Aggregation of Gold Nanoparticles for Sensitive and Selective Assay of Hepatitis B Surface Antigen. ( 29448537 )
2018
30
Pathologic femoral fracture due to tenofovir-induced Fanconi syndrome in patient with chronic hepatitis B: A case report. ( 29145330 )
2017
31
Hepatitis B in patients with hematological diseases: An update. ( 28951776 )
2017
32
Hepatitis D infection should be taken in mind while evaluating neonatal outcomes related to maternal hepatitis B infection. ( 28854842 )
2017
33
The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. ( 28109005 )
2017
34
Identification of novel OCT4 genetic variant associated with the risk of chronic hepatitis B in a Korean population. ( 27596359 )
2017
35
Effect of Nucleos(t)ide Analogue Therapy on Risk of Intra-hepatic Cholangioarcinoma in Patients With Chronic Hepatitis B. ( 28951229 )
2017
36
Response to hepatitis B vaccination in patients with liver cirrhosis. ( 28905444 )
2017
37
Drug-drug interaction potential of the hepatitis B and hepatitis D virus entry inhibitor myrcludex B assessed in vitro. ( 29134945 )
2017
38
Prevalence of hepatitis B and hepatitis C viral infections in various subtypes of B-cell non-Hodgkin lymphoma: confirmation of the association with splenic marginal zone lymphoma. ( 28362442 )
2017
39
Multiple small intestinal perforations in a patient with Hepatitis B Virus-associated Polyarteritis Nodosa. ( 28878877 )
2017
40
SOCS3 genetic variants and promoter hypermethylation in patients with chronic hepatitis B. ( 28179578 )
2017
41
DNA demethylation induces SALL4 gene re-expression in subgroups of hepatocellular carcinoma associated with Hepatitis B or C virus infection. ( 27797380 )
2017
42
Matrix Metalloproteinase 9 Facilitates Hepatitis B Virus Replication through Binding with Type I Interferon (IFN) Receptor 1 To Repress IFN/JAK/STAT Signaling. ( 28122987 )
2017
43
A Case of Primary Biliary Cirrhosis Mimicking Acute Hepatitis B in the Clinic, Republic of Korea. ( 28197333 )
2017
44
Coffee Intake Is Associated with a Lower Liver Stiffness in Patients with Non-Alcoholic Fatty Liver Disease, Hepatitis C, and Hepatitis B. ( 28075394 )
2017
45
MiRNA-target network analysis identifies potential biomarkers for Traditional Chinese Medicine (TCM) syndrome development evaluation in hepatitis B caused liver cirrhosis. ( 28887510 )
2017
46
Hypermethylation of the N-Myc Downstream-Regulated Gene 2 Promoter in Peripheral Blood Mononuclear Cells is Associated with Liver Fibrosis in Chronic Hepatitis B. ( 28202850 )
2017
47
Occult Hepatitis B Virus Infections (Often with Human Herpesvirus 7 Co-Infection) Detected in<i>Pityriasis rosea</i>Patients: A Pilot Study. ( 29263533 )
2017
48
I^I'T cells are indispensable for IL-23-mediated protection against ConA-induced hepatitis in hepatitis B virus transgenic mice. ( 28092402 )
2017
49
C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway. ( 28186991 )
2017
50
Diagnosis of coinfection by schistosomiasis and viral hepatitis B or C using 1H NMR-based metabonomics. ( 28763497 )
2017

Variations for Hepatitis B

Expression for Hepatitis B

Search GEO for disease gene expression data for Hepatitis B.

Pathways for Hepatitis B

Pathways related to Hepatitis B according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.47 DDX3X IFNA1 IFNA2 IFNG TNF
2 11.96 IFNA1 IFNA2 IFNG TNF
3
Show member pathways
11.91 IFNA1 IFNA2 IFNG TNF
4
Show member pathways
11.69 ALB F2 GGT1 IFNG TNF
5
Show member pathways
11.67 IFNA1 IFNA2 IFNG TNF
6
Show member pathways
11.62 DDB1 DDX3X IFNA1 IFNA2 LAMTOR5 TNF
7 11.5 IFNA2 IFNG TNF
8 11.18 AIP IFNG TNF
9 11.08 AFP ALB F2

GO Terms for Hepatitis B

Cellular components related to Hepatitis B according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 AFP ALB DDX3X F2 IFNA1 IFNA2
2 extracellular space GO:0005615 9.4 AFP ALB CPD DDB1 F2 GGT1

Biological processes related to Hepatitis B according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.88 APOBEC3G DDX3X IFNA1 IFNA2 MBL2
2 regulation of receptor activity GO:0010469 9.85 F2 IFNA1 IFNA2 IFNG TNF
3 defense response to virus GO:0051607 9.73 APOBEC3G IFNA1 IFNA2 IFNG
4 response to virus GO:0009615 9.62 DDX3X IFNG LAMTOR5 TNF
5 negative regulation of growth of symbiont in host GO:0044130 9.49 MBL2 TNF
6 positive regulation of viral genome replication GO:0045070 9.43 DDB1 DDX3X NR5A2
7 negative regulation of viral process GO:0048525 9.4 APOBEC3G MBL2
8 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.37 IFNG TNF
9 positive regulation of vitamin D biosynthetic process GO:0060557 9.16 IFNG TNF
10 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.13 IFNA1 IFNA2 IFNG
11 humoral immune response GO:0006959 8.92 IFNA1 IFNA2 IFNG TNF

Molecular functions related to Hepatitis B according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 IFNA1 IFNA2 IFNG TNF

Sources for Hepatitis B

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....